Peptineo's Approach to Nanomedicine

An excellent overview of nanomedicine from the European Union (EU).  It describes perfectly technologies being developed by Peptineo.  Peptineo, a nanotechnology company based in Albuquerque, New Mexico, is currently developing commercial technologies around the use of novel polymeric materials for drug delivery applications.  In particular, one material under development, acetalated dextran (Ac-DEX), has recently been used as the basis for a novel vaccine under the direction of noted academic researchers and the US Department of Defense, Defense Advanced Research Projects Agency (DARPA).  Ac-DEX is also being reviewed for applications in which it could facilitate the re-introduction of failed late-stage drug candidates into the regulatory approval process.  In this case, it is anticipated that through its ability to precisely control the release of active pharmaceutical ingredients (APIs), Ac-DEX will offer a significantly better safety profile in numerous therapeutic applications.  Peptineo is looking forward to sharing details about Ac-DEX based materials soon



Dr. George Tegos Joins Advisory Board at Peptineo to Guide Antimicrobial Pipeline and Technology Development

Albuquerque, NM,-- Peptineo, a biotechnology company focused on value recovery in Pharma, announces the appointment of George Tegos, PhD, to the company's Scientific Advisory Board. "We are extremely pleased that Dr. Tegos has joined the Peptineo Scientific Advisory Board. Dr. Tegos is recognized as an emerging scientist in antimicrobial drug discovery - with the cornerstone of his research portfolio being on the development of transformative microbial efflux inhibition strategies for emerging and re-emerging pathogens. His groundbreaking research has laid the foundation for linking fundamental genomics research and validation to preclinical efficacy studies. In fact, he and his colleagues were instrumental in the advancement of new synergistic therapeutic modalities based on small molecule efflux pump inhibitors in conjunction with conventional or photoactive antimicrobial agents. We very much look forward to Dr. Tegos’s input regarding the most efficient development of our drug delivery portfolio and related peptide-based compounds," notes Dr. Sheldon K. Jordan

 

Dr. Tegos currently maintains a research appointment at the University of New Mexico School of Medicine, Albuquerque, New Mexico, and has a visiting appointment at the Wellman Center for Photomedicine at Massachusetts General Hospital, Harvard Medical School. His research interests include drug discovery and development of new antimicrobial strategies with an emphasis on multidrug efflux system photodynamic therapy. Dr. Tegos is also a noted researcher in novel virulence and microbial pathogenicity determinants. He has published over 70 peer-reviewed articles, over 100 conference proceedings, book chapters and International abstracts, and serves as editor and ad hoc reviewer for a variety of journals and funding organizations in the US and worldwide. Dr. Tegos holds degrees from the University of Athens and the University of Ioannina Greece, and has performed research at Northeastern University and at Harvard Medical School.

 

About Peptineo

With an expanding portfolio of intellectual property and interdisciplinary technical expertise, Peptineo represents the new face of biotechnology and bioengineering. By employing a systems-based approach, Peptineo technical solutions involve drug delivery combinations including “tunable” nano-carriers, engineered peptides, re-formulated pharmaceuticals, and as appropriate, recombinant proteins. Additionally, Peptineo is developing technologies that will greatly enhance and accelerate the drug discovery process.

 

Media contact: VP of Business Development, +1 (855) FULL-BIO (385-5246)

609 Broadway Blvd NE, Albuquerque, New Mexico 87102

Website: (http://www.peptineo.com) Email: info@peptineo.com

 

Source: Peptineo, LLC

 

Related Links

http://www.peptineo.com

http://angel.co/peptineo

http://www.crunchbase.com/company/peptineo

http://www.linkedin.com/company/peptineo

https://plus.google.com/+Peptineo

https://www.facebook.com/Peptineo

Dr. Eric Bachelder Joins Advisory Board at Peptineo

Albuquerque, NM, January 18, 2014 -- Sheldon K. Jordan, PhD, President and CEO, Peptineo, announces the appointment of Eric Bachelder, PhD, to the company's Scientific Advisory Board. "We are extremely pleased that Dr. Bachelder has joined the Peptineo Scientific Advisory Board. Dr. Bachelder is recognized as an emerging scientist in the development of novel drug delivery moieties for the treatment of inflammation and other debilitating diseases. He and his colleagues were instrumental in the advancement of a new class of polymers that have implications for vaccines, antibiotics, siRNA delivery, and for other diseases with unmet therapeutic needs. We very much look forward to Dr. Bachelder's input regarding the most efficient development of our drug delivery portfolio and related peptide-based compounds," says Dr. Jordan.
.
Dr. Bachelder currently maintains a research appointment at the Ohio State University, Columbus, Ohio. He maintains various academic collaborations that focus on advanced immune therapies, nano- and micro-particulate carriers, and the formulation of novel polymers. Recent publications include a novel experimental vaccine for Bacillus Anthracis, encapsulation and storage of a model protein outside the pharmaceutical cold-chain with implications for vaccines, treatment therapies for infection, and development of tolerogenic vaccines. Dr. Bachelder holds degrees from Michigan State University and the University of Nebraska and has performed research at the National Institutes of Health and the University of California at Berkeley.

About Peptineo
With an expanding portfolio of intellectual property and interdisciplinary technical expertise, Peptineo represents the new face of biotechnology and bioengineering. By employing a systems-based approach, Peptineo technical solutions involve drug delivery combinations including “tunable” nano-carriers, engineered peptides, re-formulated pharmaceuticals, and as appropriate, recombinant proteins. Additionally, Peptineo is developing technologies that will greatly enhance and accelerate the drug discovery process.

Media contact: VP of Business Development, +1 (855) FULL-BIO (385-5246)
609 Broadway Blvd NE, Albuquerque, New Mexico 87102
Website: (http://www.peptineo.com) Email: info@peptineo.com

Source: Peptineo, LLC

Related Links
http://www.peptineo.com
http://angel.co/peptineo
http://www.crunchbase.com/company/peptineo
http://www.linkedin.com/company/peptineo
https://plus.google.com/+Peptineo

Kimberley Beauford Joins Peptineo as Vice President of Human Capital

Albuquerque, NM, January 12, 2014--Industry veteran and accomplished executive, Kimberley Beauford has joined Peptineo as its new vice president of human capital. Beauford brings over 14 years of proven expertise in the delivery of innovative, strategic human capital programs to the finance and healthcare industries. Prior to joining Peptineo, Beauford was in progressive leadership roles serving as a key executive facilitator in employee relations, labor relations, recruitment, leadership and employee development, strategic planning, organizational development, conflict resolution, training, compensation, benefits and worker’s compensation. Beauford started her professional Human Resources career with the world’s second largest professional services firm, PricewaterhouseCoopers in Houston, Texas. After a year of HR excellence in Houston, she transferred to the New York City office, where she worked as an Experience Recruiter, sourcing out the best and the brightest candidates. She then was promoted to a Senior Associate in the firm, where she worked as a HR Generalist partnering with her internal clients of Tax & Legal professionals. After 9/11, she left the city for a HR Healthcare Leadership position in Staten Island, NY, where she was the HR Director for one of the most recognized Long-Term Healthcare Centers in NY. She provided HR leadership to over 900 employees who were 1199SEIU Union and Non-Union employees and successfully built a strong trusting relationship with union delegates, employees, management, and c-level administration.

 

Beauford is not only a HR Professional, but she is also a successful entrepreneur and business owner. Her interests currently center on commercial retail opportunities and real estate. Recently, the National Association of Women Business Owners, which honors women business owners who have overcome unusual hardships to succeed in their businesses, honored her with the 2012 Tough Cookie Award. Beauford holds a Bachelor of Sciencedegree and a Master of Arts degree from the University of Houston-Clear Lake in Behavioral Science, specializing in Industrial/Organizational Psychology.

 

About Peptineo

With an expanding portfolio of intellectual property and interdisciplinary technical expertise, Peptineo represents the new face of biotechnology and bioengineering. By employing a systems-based approach, Peptineo technical solutions involve drug delivery combinations including “tunable” nano-carriers, engineered peptides, re-formulated pharmaceuticals, and as appropriate, recombinant proteins. Additionally, Peptineo is developing technologies that will greatly enhance and accelerate the drug discovery process.

 

Media contact: VP of Business Development, +1 (855) FULL-BIO (385-5246)

609 Broadway Blvd NE, Albuquerque, New Mexico 87102

Website: http://www.peptineo.com Email: info@peptineo.com

Source: Peptineo, LLC

 

Related Links

http://www.peptineo.com

http://angel.co/peptineo

http://www.crunchbase.com/company/peptineo

http://www.linkedin.com/company/peptineo

https://plus.google.com/+Peptineo

https://www.facebook.com/Peptineo

Peptineo Inks Exclusive Option for Drug Delivery Technologies

ALBUQUERQUE, New Mexico- Peptineo, a privately held biotechnology company, announced today that the company has inked an exclusive option for a broad set of nanotechnology patents in the area of drug delivery. Under this agreement, Peptineo will work to commercialize drug delivery technologies developed in the laboratories of Dr. Carolyn Bertozzi and Dr. Jean M.J. Fréchet.  “Securing an option agreement marks a significant event in the evolution of Peptineo and will enhance on-going research efforts within the company,” noted Dr. Sheldon Keith Jordan, CEO.  “For Peptineo, Dr. Bertozzi’s and Dr. Fréchet’s collective body of research represent the highest standard of scientific expertise and will afford Peptineo multiple opportunities to address unmet drug delivery challenges in many therapeutic areas,” commented Dr. Jordan.

While it is often useful to release therapeutic agents under mildly acidic conditions, few existing materials developed for drug delivery are both acid-sensitive and biodegradable/bioerodible.  To address this gap, Jean Fréchet and a team of scientists have developed a new class of polymers that can encapsulate proteins, DNA/RNA-based materials, and other bioactive agents for vaccines, drug delivery, and gene therapy.  A key feature for this class of polymers is that they can be employed in any application that necessitates materials with precise control over the release of encapsulated cargoes.  In the human body, these polymers will be able to quickly release their payloads or be eroded over time -breaking down into neutral byproducts that can be safely eliminated. Materials made from the polymers can be engineered to degrade at specific rates, ranging from a day to many months at physiological pH, depending on the formulation used. Additionally, these same materials will allow for greater variation in the type of encapsulated therapeutic materials, targeted cell types, and drug release kinetics than are currently available -including microencapsulation materials like poly-(lactide-co glycolic acid) (PLGA).

With regard to research efforts led by Carolyn Bertozzi, she and her colleagues have developed a method for creating high-purity, nano-sized polymer particles that display specific biological ligands on their surfaces.  The resultant nanoparticles are hollow, spherical, polymerized liposomes that bind to biological targets and can be used as an inhibitor or be used for delivering a drug loaded in its interior. This technology forms the basis for a new class of materials that have great therapeutic potential.  Briefly, the material starts out as a membrane in the spherical form of a liposome that is self-assembled from individual monomers. Monomers that bind to pathogens (such as influenza virus) or bind to disease sites in-vivo (inflamed tissue) are incorporated into the self-assembling mixture –thereby providing critical in-vivo targeting capabilities.   Finally, a quick and efficient polymerization by light gives a solid shell to the resultant nanoparticle.

About Carolyn R. Bertozzi, PhD

Carolyn Bertozzi is the T.Z. and Irmgard Chu Distinguished Professor of Chemistry and Professor of Molecular and Cell Biology, an Investigator of the Howard Hughes Medical Institute, and Senior Faculty Scientist.  She is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the German Academy of Sciences Leopoldina.

About Jean M.J. Fréchet, PhD

Professor Fréchet, a polymer chemist best known for his contributions in a wide range of fields, including modern electronics and biotechnology, has authored approximately 900 scientific papers and patents, has over 60,000 citations with an H-index of 128.  He was recently the Henry Rapoport Chair of Organic Chemistry. In addition, he is currently the Vice-President for research at the King Abdullah University of Science and Technology.

About Peptineo

With an expanding portfolio of intellectual property and interdisciplinary technical expertise, Peptineo represents the new face of biotechnology and bioengineering. By employing a systems-based approach, Peptineo technical solutions involve drug delivery combinations including “tunable” nano-carriers, engineered peptides, re-formulated pharmaceuticals, and as appropriate, recombinant proteins. Additionally, Peptineo is developing technologies that will greatly enhance and accelerate the drug discovery process.

 

Media contact:  VP of Business Development, +1 (855) FULL-BIO  (385-5246)

609 Broadway Blvd NE, Albuquerque, New Mexico 87102

Website: (http://www.peptineo.com)     Email:  info@peptineo.com

 

SOURCE: Peptineo, LLC

RELATED LINKS

http://www.peptineo.com

http://angel.co/peptineo

http://www.crunchbase.com/company/peptineo

http://www.linkedin.com/company/peptineo

https://plus.google.com/+Peptineo

https://www.facebook.com/Peptineo

Crowd Sourcing for Medical Research

There is a great site out on the web. This site employs crowdfunding to help support medical research. As you skim the site, you see projects ranging from cancer research to lung transplants. Surprisingly, several of the projects are fully funded. It is definitely worth a look. 

 

https://www.consano.org/